亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A multicenter, single-arm, phase II study of nivolumab in patients with biliary tract cancer with a PD-L1 combined positive score ≥ 1.

医学 内科学 吉西他滨 临床终点 胆囊癌 养生 无容量 胃肠病学 临床研究阶段 癌症 进行性疾病 肿瘤科 外科 毒性 临床试验 化疗 免疫疗法
作者
Masayuki Furukawa,Makoto Ueno,Daisuke Sakai,Kota Ouchi,Yasuo Hamamoto,Hiroshi Aikata,Masato Ozaka,Hidetaka Tsumura,Kunihiro Tsuji,Shoji Kubo,Tomohiro Nishina,Akio Katanuma,Chigusa Morizane,Masafumi Ikeda,Nobumasa Mizuno,Takashi Inagaki,Kazuhiko Shioji,Junji Furuse
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:41 (4_suppl): 533-533
标识
DOI:10.1200/jco.2023.41.4_suppl.533
摘要

533 Background: Patients with advanced biliary tract cancer (BTC) have a poor prognosis, and high unmet medical needs still exist for the treatment of this disease. Nivolumab has shown its effectiveness against multiple cancer types, especially those with PD-L1 expression. This study assessed the efficacy and safety of nivolumab in BTC patients with a combined positive score (CPS) ≥ 1 who were refractory or intolerant to the standard of care (SOC): gemcitabine, cisplatin and tegafur/gimeracil/oteracil (S-1). Methods: This was a single-arm, multicenter, open-label, prospective phase II study. Key eligibility criteria were as follows: having unresectable or recurrent BTC (intrahepatic bile duct cancer, extrahepatic bile duct cancer, gallbladder cancer, or ampullary cancer); being refractory or intolerant to SOC; having adequate hepatic, renal and hematological function; and having a CPS ≥ 1 in central assessment. Patients received nivolumab (480 mg, every 4 weeks) until disease progression, clinical deterioration, or unacceptable toxicity. The primary endpoint was objective response rate (ORR) assessed by the central review according to RECIST 1.1. The secondary endpoints included overall survival (OS), progression-free survival (PFS), and safety. Results: A total of 84 patients were enrolled between Mar 11, 2020 and Mar 15, 2021, of them 12 received one regimen and 72 received two or more regimens. The median follow-up period was 6.90 months. ORR per central assessment was 10.7% (CR: 3.6%, PR: 7.1%), and ORR per investigator assessment was 15.5% (CR: 2.4%, PR: 13.1%). The median PFS per central and investigator assessment was 1.02 (95% CI 0.95–1.77) months and 2.48 (95% CI 1.87–2.83) months, respectively. The median OS was 6.90 (95% CI 5.26–9.20) months. The median duration of response per central and investigator assessment was not reached (range 2.8–13.0+) and 10.15 (range 2.0–12.8+) months, respectively. The 1-year survival rate was 25.3% (95% CI 15.4–36.4). The most frequent treatment-related adverse events were pyrexia (19.0%), pruritus (16.7%), and decreased appetite (13.1%). Conclusions: Nivolumab may have some activity with a durable response and a manageable safety profile in heavily treated BTC patients with CPS ≥ 1. Clinical trial information: JapicCTI-205097 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
暮色发布了新的文献求助20
3秒前
独特的紫雪完成签到,获得积分10
7秒前
25秒前
无花果的应助被wanglijia采纳,获得10
26秒前
追寻从寒完成签到,获得积分10
27秒前
自信醉香完成签到,获得积分10
27秒前
絮絮徐发布了新的文献求助10
40秒前
niein完成签到,获得积分10
41秒前
香蕉觅云的应助被甜甜的悲采纳,获得10
44秒前
俏皮含双完成签到,获得积分10
51秒前
53秒前
56秒前
christy发布了新的文献求助10
57秒前
隐形曼青的应助被xiaoping采纳,获得10
1分钟前
1分钟前
傻傻的冰烟完成签到,获得积分10
1分钟前
1分钟前
你没事吧完成签到 ,获得积分10
1分钟前
凤苓发布了新的文献求助10
1分钟前
栀鸢完成签到,获得积分10
1分钟前
机灵的夜梅完成签到,获得积分10
1分钟前
1分钟前
清秀小霸王完成签到 ,获得积分10
1分钟前
molihuakai的应助被科研通管家采纳,获得10
1分钟前
情怀的应助被科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
脑洞疼的应助被科研通管家采纳,获得10
1分钟前
Owen的应助被甜甜的悲采纳,获得10
1分钟前
忧郁思远完成签到,获得积分10
1分钟前
凤苓完成签到,获得积分10
1分钟前
赘婿的应助被含糊的电源采纳,获得10
1分钟前
lyw发布了新的文献求助10
1分钟前
1分钟前
小马甲的应助被甜甜的悲采纳,获得10
1分钟前
专注的夜天完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
Ray的应助被niein采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165968
求助须知:如何正确求助?哪些是违规求助? 9559406
关于积分的说明 21750034
捐赠科研通 7756757
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473672